ATNM News and Press, Actinium Pharmaceuticals Inc. From 10/04/23

Actinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell Therapy PR Newswire - Ongoing clinical trial is the first ever to combine targeted radiotherapy conditi...

Actinium Pharma Highlights Abstract Accepted for Poster Presentation at the SITC 38th Annual Meeting PR Newswire NEW YORK , Sept. 27, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the develop...

2023-09-15 19:02:20 ET Summary Actinium is making radiolabeled antibodies for use in hematologic cancers. Previously reported phase 3 trial results give a strong indicator of success at the regulatory level. No respect from the market means Actinium could be in a good position...

2023-09-10 15:17:31 ET HSBC initiated coverage of 11 US biopharma stocks this week, adding IQVIA, Zoetis, bluebird and Actinium Pharmaceuticals to its “buy” ratings list. IQVIA ( NYSE: IQV ) and Zoetis ( NYSE: ZTS ) were labeled “quality growthȁ...

Actinium Pharma Presents Survival Data from Extended Follow-Up from Actimab-A + CLAG-M Trial and Preclinical Data Supporting Program Expansion with FLT3 Inhibitor Combinations at SOHO PR Newswire - Extended follow-up in the Actimab-A + CLAG-M trial showed median overall sur...

Actinium Pharma Highlights Three Abstracts Accepted for Poster Presentation at the SOHO 2023 Annual Meeting PR Newswire - First ever data demonstrating anti-leukemic effect of Actimab-A in FLT3 Mutant AML models NEW YORK , Aug. 31, 2023 /PRNewswire/ --&#x...

Actinium Pharma Highlights Abstracts Accepted for Oral and Poster Presentation at the EANM 2023 Congress PR Newswire NEW YORK , Aug. 21, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the developm...

Actinium Pharma to Present at the 2nd Annual Targeted Radiopharmaceuticals Summit PR Newswire NEW YORK , July 24, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted rad...

SNMMI 2023 Annual Meeting Abstract of the Year Awarded to Actinium's Iomab-B Phase 3 SIERRA Data PR Newswire - SNMMI Henry N. Wagner, Jr., Abstract of the Year award represents top selection out of more than 1,500 abstracts accepted for presentation NEW YORK ...

Actinium Pharma Highlights Six Abstracts Accepted for Oral and Poster Presentation at the SNMMI 2023 Annual Meeting PR Newswire NEW YORK , June 23, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in th...